



NIH PUBLIC ACCESS

Author Manuscript

Mucosal Immunol. Author manuscript; available in PMC 2014 March 03.

Published in final edited form as:

Mucosal Immunol. 2011 January ; 4(1): 22–30. doi:10.1038/mi.2010.61.

Helicobacter hepaticus infection in mice: Models for understanding lower bowel inflammation and cancer

JG Fox, DVM^{1,*}, Z Ge, PhD¹, MT Whary, DVM, PhD¹, SE Erdman, DVM¹, and BH Horwitz, MD, PhD²¹ Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA² Department of Pathology, Brigham and Women's Hospital, Boston, MA

Abstract

Pioneering work in the 1990's first linked a novel microaerobic bacterium, *Helicobacter hepaticus*, with active chronic hepatitis and IBD in several murine models. Targeted *H. hepaticus* infection experiments subsequently demonstrated its ability to induce colitis, colorectal cancer, and extra-intestinal diseases in a number of mouse strains with defects in immune function and/or regulation. *Helicobacter hepaticus* is now widely utilized as a model system to dissect how intestinal microbiota interact with the host to produce both inflammatory and tolerogenic responses. This model has been used to make important advances in understanding factors that regulate both acquired and innate immune response within the intestine. Further, it has been an effective tool to help define the function of regulatory T cells, including their ability to directly inhibit the innate inflammatory response to gut microbiota. The complete genomic sequence of *H. hepaticus* has advanced the identification of several virulence factors and aided in the elucidation of *H. hepaticus* pathogenesis. Delineating targets of *H. hepaticus* virulence factors could facilitate novel approaches to treating microbially induced lower bowel inflammatory diseases.

Keywords

Helicobacter hepaticus; mouse models; IBD

Initial isolation and characterization of *H. hepaticus* and *H. bilis*

Since the isolation and characterization of *Helicobacter pylori*, the etiologic agent of peptic ulcer disease in 1983, a number of other *Helicobacter* species have been isolated, many of which can produce serious non-gastric disease in their respective hosts. *Helicobacter* species that colonize the lower bowel and biliary tract of mice have been associated with the development of colitis resembling human inflammatory bowel disease (IBD) in susceptible hosts. Further, *H. hepaticus* infection has been demonstrated to exacerbate the development of cancer at both intestinal and extraintestinal sites. The most well studied member of this group of enterohepatic *Helicobacter* species (EHS) is *Helicobacter hepaticus*. In this review we will focus on the initial identification of *H. hepaticus*, the basis for *H. hepaticus*-induced lower bowel inflammation, and the characterization of bacterial virulence factors.

In the early 1990's, an active chronic hepatitis was detected in several inbred strains of mice including A/JCr, originating from a barrier-maintained facility. A distinctive morphological

*Corresponding author. Mailing address: Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Building 16-825, Cambridge, MA 02139. Phone (617) 253-1735. Fax: (617) 258-5708. jgfox@mit.edu.

All authors verify that they have 'no conflict'.

pattern of liver damage was noted which had not been previously identified in mice. Using a special silver stain, a spiral-like organism was observed in the liver. Infected A/JCr mice were then shipped to our laboratory for characterization and diagnostic evaluation. A microaerobic bacterium was consistently isolated from the liver and colon of these mice between 3 and 18 months of age. By biochemical and molecular methodologies these bacteria were confirmed to represent a new *Helicobacter* sp. which we named *H. hepaticus*¹⁻³. Shortly after the isolation of *H. hepaticus*, we isolated a fusiform bacterium from the liver, bile, and lower intestine of aged, inbred mice. On the basis of 16S rRNA gene sequence analysis, the organism was classified as a novel *Helicobacter* sp., *H. bilis*.

Currently there are 9 formally named EHS isolated from mice as well as several other novel *Helicobacter* spp. awaiting formal naming. Most recently, *H. pullorum*, a human pathogen, has been isolated from commercial, barrier maintained mice⁴. Surveys conducted in 1995 and 2007 indicated that *H. hepaticus* as well as other EHS have a worldwide distribution in academic and commercial mice^{5, 6}. Contrary to the earlier survey, no *Helicobacter* spp., however, were found in mice in 2007 from advertised *Helicobacter*-free production areas from two U.S. vendors. These results demonstrated that infection with EHS is wide spread in most if not all mouse colonies used for experimental investigations.

Spontaneous IBD in immunodeficient and genetically engineered mice: Association with *Helicobacter* spp

Prior to the isolation of EHS, it had been speculated that microflora might play an important role in the etiology of spontaneous colitis that developed in a number of immunodeficient laboratory mouse strains including IL-10-deficient, *scid*, and RAG. Berg et al. also demonstrated that inbred mice on different strain backgrounds with undefined intestinal flora influenced the degree of colitis and lower bowel adenocarcinoma noted in mice; C57BL IL10^{-/-} were less prone to develop colitis and carcinoma, Balbc IL10^{-/-} were intermediate in susceptibility and 129 IL10^{-/-} mice developed the most severe disease⁷. Once identified, we found that while *H. hepaticus* infection could be demonstrated in a number of immunologically normal mice without colitis, it was strongly associated with chronic proliferative typhlitis, colitis, and rectal prolapse in several immunodeficient mouse strains housed at NCI and MIT^{8, 9}. The specific pathogen-free health status of these colonies was verified to include lack of serum antibodies to murine viruses and negative cultures for respiratory pathogens, *Salmonella* sp., and *Citrobacter rodentium*. These findings suggested infection with *H. hepaticus* was strongly associated with the development of colitis in a number of laboratory mouse strains, and raised the question of whether *H. hepaticus* might be an etiologic agent of murine colitis.

Establishing the Link Between *Helicobacter* spp. and IBD

To establish the link between *H. hepaticus* and the development of colitis, we demonstrated that *H. hepaticus* inoculated into *Helicobacter* spp. free defined flora C.B. 17 *scid* mice reconstituted with CD45RB^{high} T cells resulted in severe IBD, similar to that noted with human disease¹⁰. The expression of typhlitis and colitis was statistically less severe in defined flora *scid* mice that had been reconstituted with T cells but not infected with *H. hepaticus* when compared to reconstituted *scid* mice infected with *H. hepaticus*¹⁰, demonstrating that infection with this single species could significantly exacerbate colitis in a murine disease model^{11, 12}. Similar results were obtained following targeted infection of C57BL IL-10-deficient mice with *H. hepaticus*^{13, 14}. Targeted infection experiments have now demonstrated that *H. hepaticus* is able to induce colitis and in some cases lower bowel carcinoma in a number of mouse strains with defects in immune function and/or regulation (Table 1). Interestingly, the same strain susceptibility noted by Berg et al in IL10^{-/-} mice

was also documented in Rag^{-/-} mice developing colitis associated lower bowel carcinoma when experimentally infected with *H. hepaticus*^{7, 15}.

Basis of the GI inflammatory response to *H. hepaticus*

The experiments described indicate that *H. hepaticus* infection can induce colitis in certain susceptible mouse strains, but the nature of the inflammatory response and why certain strains were susceptible required further investigation. Seminal experiments from the early 1990's demonstrated that mice lacking IL-10 developed spontaneous colitis, which was significantly less severe when mice were housed in SPF conditions, suggesting enhanced susceptibility to microbiota induced inflammation¹⁶. In contrast to *H. hepaticus* monoassociated C57BL IL10^{-/-} mice which did not develop colitis, Kullberg and co-workers directly demonstrated that targeted infection of SPF housed C57BL IL-10 mice with *H. hepaticus* significantly exacerbated the development of colitis^{13, 17}. The inflammatory response in the *H. hepaticus*-infected C57BL IL-10-deficient mice was characterized by a Th1-like cytokine profile^{13, 18}. More recently these results have been replicated by demonstrating that wild-type (WT) C57BL mice treated with an antibody directed at the IL10 receptor (anti-IL-10R), but not those treated with a control antibody, develop colitis following infection with *H. hepaticus*¹⁹. Colitis in anti-IL-10R treated mice is characterized by increased expression of mRNA coding for IFN- γ and IL-17 within the colon. Mesenteric lymph node cells (MLNs) derived from *H. hepaticus*-infected mice treated with anti-IL-10R secreted higher levels of IL-17 and IFN- γ compared to control mesenteric lymph node cells following exposure to soluble helicobacter antigen¹⁹. Mice deficient in IL-12p40 but not those deficient in IL-12p35 were resistant to *H. hepaticus*-induced colitis following anti-IL-10R treatment, which was associated with decreased expression of IFN- γ and IL-17, suggesting that IL-23 rather than IL-12p70 was necessary for the generation of both Th1 and Th17 responses observed following *H. hepaticus* infection. These experiments indicated that *H. hepaticus* can induce antigen-specific Th1 and Th17 responses in mice with impaired IL-10 signaling.

While *H. hepaticus* infection of mice with impaired IL-10 signaling induces CD4-mediated Th1 and Th17 responses, the exact role of both IFN- γ and IL-17 in *H. hepaticus*-mediated colitis has been more difficult to discern. Initial experiments with an IFN- γ depleting antibody suggested that IFN- γ was necessary for *H. hepaticus* to induce colitis in IL-10-deficient mice¹³. However, the severity of *H. hepaticus*-induced colitis in mice doubly-deficient for IL-10 and IFN- γ was very similar to that in mice lacking IL-10 alone¹⁸. Further, whereas *H. hepaticus*-induced inflammation within the colon of IFN- γ -deficient mice treated with anti-IL-10R was decreased compared to similarly treated WT mice, there was no difference in the level of inflammation in the cecum between genotypes¹⁹. Although to our knowledge, the role of IL-17 in regulating *H. hepaticus*-induced inflammation in mice with impaired IL-10 signaling has not been directly tested, there are conflicting results from experiments testing the role of IL-17 in the development of colitis that develops follow the adoptive transfer of CD4⁺CD45RB^{high} cells into lymphocyte-deficient hosts^{20, 21}. Further, as it has been suggested that other Th17 cell-derived cytokines such as IL-17F²⁰ and IL-22^{22, 23} can modulate disease severity in T cell-dependent models of colitis, the role of these cytokines in *H. hepaticus*-dependent colitis requires additional study.

Although the exact role of T helper subsets in the development of *H. hepaticus*-induced colitis in susceptible hosts remains to be determined, increasing evidence has focused attention on the innate inflammatory response to *H. hepaticus*. Early studies demonstrated that *H. hepaticus* could induce colitis in certain strains of lymphocyte-deficient mice including *scid* and 129SvEv/Rag^{-/-}^{10, 24-27}, and progressed to colonic carcinoma with neoplastic peritoneal invasion in some murine models^{24, 28}. *H. hepaticus*-induced innate

colitis appeared to be dependent upon IL-23, as antibody depletion of both IL-12 p40 and IL-12 p19 (the components of IL-23) inhibited *H. hepaticus*-induced colitis in 129SvEv/Rag^{-/-} mice²⁹. Antibody depletion assays have also demonstrated an important role for TNF in *H. hepaticus*-induced innate colitis²⁵.

Surprisingly, even in the innate colitis model, *H. hepaticus* infection induced robust levels of the T helper associated cytokines IL-17 and IFN- γ within the colon of 129SvEv/Rag^{-/-} mice²⁹, and treatment of *H. hepaticus*-infected 129SvEv/Rag^{-/-} mice with either IL-17 or IFN- γ depleting antibody ameliorated colitis³⁰. This suggested that cells of the innate immune system express IL-17 and IFN within the colon following *H. hepaticus* infection. Indeed, in 129SvEv/Rag^{-/-} mice infected with *H. hepaticus*, there was a marked increase in the percentage of colonic lamina propria (LP) cells that stain positively for IL-17 alone or both IL-17 and IFN- γ following overnight stimulation with IL-23³⁰. These IL-17⁺ cells lacked lineage markers (CD11b, GR1, B220), but expressed high levels of Thy1⁺³⁰, and thus bear similarities to a previously described rare population of lamina propria cells termed Lymphoid Tissue inducer-like (LTi-like) cells^{31,32}. Some LTi-like cells express CD4 on their cell surface³¹, while these newly described IL-17⁺ innate lymphoid cells do not³⁰. However they share a number of other cell surface markers including IL-7R α ^{30,31}. Interestingly, there was a marked increase in the frequency of Thy1^{high} innate lymphoid cells within the colonic lamina propria of 129SvEv/Rag^{-/-} following *H. hepaticus* infection, and when isolated by sorting, these cells produced IFN- γ , IL-17, and IL-22 after overnight culture, which was enhanced by treatment with IL-23³⁰.

It has previously been shown that the development of LTi and LTi-like cells, as well as classic Th17 cells require the transcription factor, ROR γ t³¹⁻³³. Interestingly, *H. hepaticus*-induced innate-Thy1^{high} LP cells expressed higher levels of ROR γ t than remaining Thy1⁻ LP cells³⁰, and both C57BL/6Rag^{-/-} mice treated with anti-Thy1 antibody, or C57BL/6Rag^{-/-} mice that lacked the gene for ROR γ t, were resistant to anti-CD40-induced innate colitis³⁰. These data strongly suggest that Thy1⁺ ROR γ t-expressing innate lymphoid cell plays a critical role in driving intestinal inflammation. Further, if these innate lymphoid cells require the IL-7 receptor for their survival and/or expansion in similar fashion to LTi cells³⁴, this could explain the earlier observation that *H. hepaticus* is unable to induce colitis in 129SvEv/Rag^{-/-} mice that also lack IL-7²⁷.

These studies argue that innate immune mechanisms play a critical role in the ability of *H. hepaticus* to induce colitis in susceptible hosts. However, it is important to recognize that *H. hepaticus* infection does not induce colitis in most WT mouse strains despite persistent infection, suggesting that a lymphocyte-mediated mechanism inhibits *H. hepaticus*-induced innate inflammation. Consistent with this, several groups have shown that the adoptive transfer of CD4⁺CD25⁺ T regulatory-cells into 129SvEv/Rag^{-/-} mice can inhibit the development of colitis following *H. hepaticus* infection^{25,28}. Inhibition depends upon the ability of transferred cells to express IL-10, as IL-10-deficient CD4⁺CD25⁺ T cells are unable to inhibit *H. hepaticus*-induced innate inflammation, and in fact appear to exacerbate disease^{24,25}. Remarkably, transfer of CD4⁺CD25⁺ T regulatory cells into *H. hepaticus*-infected 129SvEv/Rag^{-/-} mice with colitis leads to rapid resolution of disease^{24,35}. Several studies revealed that potency of CD4⁺CD25⁺ to protect against or treat IBD can be enhanced by *H. hepaticus* infection of donor mice^{36,37}. Thus CD4⁺CD25⁺ T regulatory cells can both inhibit and treat *H. hepaticus*-induced innate inflammation in the lower bowel, based on an IL-10-dependent mechanism. Interestingly, CD25⁺ cells are not the only CD4⁺ subtype with regulatory activity, as it has been demonstrated that CD4⁺CD45RB^{low}CD25⁻ cells harvested from *H. hepaticus* infected C57BL/10 mice are potent inhibitors of colitis induced by adoptive transfer of IL-10-deficient CD4⁺ T cells into *H. hepaticus*-infected C57BL/10Rag^{-/-} mice³⁶.

Experiments described above indicating that the recognition of *H. hepaticus* by the innate immune system plays a key role in regulating the ensuing inflammatory response in the lower bowel, suggest that understanding the innate inflammatory signaling pathways and receptors utilized by *H. hepaticus* could lead to important insights into the basis of microbiota-driven colonic inflammation. *H. hepaticus* challenge of ex vivo cultured bone marrow-derived macrophages induces activation of both the NF- κ B and ERK pathways^{26, 38}. Evidence for both pro and anti-inflammatory roles for individual NF- κ B subunits in the response to *H. hepaticus* come from experiments demonstrating that 129SvEv/Rag^{-/-} mice that also lack the NF- κ B subunit c-Rel are resistant to *H. hepaticus*-induced colonic inflammation³⁹, while 129SvEv mice that lack the p50/p105 subunit of NF- κ B are sensitized to *H. hepaticus*-induced colitis, based on a defect within the innate immune system^{26, 40}.

Identifying the innate immune receptors responsible for inducing inflammatory signaling in response to *Helicobacter spp.* infection is an active area of research. Whole *H. hepaticus* bacteria are able to induce NF- κ B activation in HEK293 cells transfected with TLR2 but not those transfected with TLR4⁴¹. However, a recent study demonstrated that the absence of TLR2 in 129SvEv/Rag^{-/-} mice does not influence the severity of the *H. hepaticus*-induced colitis⁴². Nonetheless, there is strong evidence suggesting the involvement of TLRs in mediating the in vivo inflammatory response to *H. hepaticus* as irradiated 129SvEv/Rag^{-/-} reconstituted with Myd88 deficient bone marrow cells are resistant to *H. hepaticus*-induced innate colitis⁴³.

Intracellular receptors of the Nod family play an important role in recognizing bacterial products such as peptidoglycan that are injected by bacterial secretion systems⁴⁴. It has recently been reported that the genome of *H. hepaticus* codes for a type VI secretion system that may function to inject substrates into host epithelial cells⁴⁵. Indeed, it has been suggested that the ability of *H. muridarum*, a murine EHS, to induce NF- κ B reported activity in HEK293 cells depends upon Nod1⁴⁶. Although, of note, *H. hepaticus* is a very poor inducer of NF- κ B activation in HEK293 cells⁴⁶, and a weak inducer of inflammatory gene expression in the murine intestinal crypt epithelial cells (m-IC_{c12} cells)⁴⁷, suggesting that *H. hepaticus* is unlikely to engage Nod1 in these epithelial cell lines. In contrast, it has been found that *H. hepaticus*, as well as LPS derived from *H. hepaticus*, can inhibit TLR4 induced inflammatory gene expression in m-IC_{c12} cells⁴⁷, raising the possibility that *H. hepaticus* may have prominent anti-inflammatory properties on epithelial cells. An anti-inflammatory role for an *H. hepaticus*-derived product is supported by studies showing that an *H. hepaticus* mutant lacking the type VI secretion system colonized the intestine of C57BL/6RAG^{-/-} recipients of CD4⁺CD45RB^{hi} T cells to higher levels than the WT *H. hepaticus* strain, and induced elevated levels of inflammatory gene expression⁴⁵. Finally, a role for Nod2 in recognition of *H. hepaticus* has been suggested by studies demonstrating higher levels of *H. hepaticus* in infected Nod2-deficient C57BL/6 mice than in infected WT mice, although intestinal pathology was not detected following infection of either WT or Nod2-deficient mice⁴⁸.

***Helicobacter hepaticus* infection modulates tumorigenesis at intestinal and extra-intestinal sites**

At the time of initial characterization in A/JCr mice, it was recognized that in addition to active chronic hepatitis, infection with *H. hepaticus* was also associated with the development of hepatocellular carcinoma in A/JCr as well as live tumor development in AXB, B₆C₃ and a substrain of C57BL mice^{1, 3, 49-52}. Previous studies using germ-free mice link chronic bacterial infection with chronic inflammatory diseases in the lower bowel⁵³. Targeted bacterial infection with *H. hepaticus* in 129SvEv/Rag2^{-/-} mice lead to colitis-

associated colorectal cancer (CRC) with malignancy invading the peritoneal cavity^{24, 28}. Gut bacteria-induced lesions in 129SvEv/Rag2^{-/-} mice resembled neoplasia in human patients⁵⁴ with IBD, in that carcinoma clearly arises from colitis-associated dysplastic epithelial foci that become locally invasive⁵⁵. The finding that 129SvEv/Rag2^{-/-} mice lacking lymphocytes exhibited CRC demonstrated that innate immunity is sufficient for development of carcinoma²⁸. However, immunologically intact 129 wild type mice infected with *H. hepaticus* did not develop carcinoma, showing that IL-10-dependent activities of adaptive immune cells normally serve to reinforce homeostasis and prevent cancer in the lower bowel^{28, 37}. Adoptive transfer studies using CD4⁺ cell subsets demonstrated that an imbalance between IL-6, IL-10 and Tgf- β increased risk of neoplastic epithelial invasion³⁷. Interestingly, *H. hepaticus*-induced malignancy in the 129SvEv/Rag2^{-/-} mice was readily reversible by blocking underlying bacteria-driven inflammation with antibodies directed at TNF and IL-6^{37, 56}.

Pathogenic gut microbial infections have also been shown to trigger development of intestinal adenomatous polyps in mice with a mutated Apc gene (Apc^{Min/+} or Min)⁵⁷. Mice heterozygous for Apc gene (Apc^{Min/+}) develop a large number of intestinal polyps by 3 months of age⁵⁸. This pre-neoplastic process has been shown to be inhibited by adoptive transfer of interleukin 10 (IL-10)-dependent T_{Reg} cells, and depends on their ability to produce IL-10^{59, 60}. Targeted infection with *H. hepaticus* increases multiplicity and malignancy of intestinal polyps in the Apc^{Min/+} mouse model by an inflammation-associated TNF- α -dependent mechanism⁵⁷. Likewise, infection with other pathogenic enteric microbiota including *Citrobacter rodentium*⁶¹ and an enterotoxigenic *Bacteroides fragilis*⁶² have been shown to promote colon tumorigenesis in Apc^{Min/+} mice. Recent evidence points to key roles for IL-17 as well as IL-23 in colonic hyperplasia and tumor formation^{62, 63}. Taken together these models may provide novel mechanistic insights in colon carcinogenesis in humans.

More recently, experiments examining the ability of GI tract bacteria and subpopulations of immune cells to induce or inhibit IBD have revealed surprising insights into extra-intestinal carcinogenesis. For example, *H. hepaticus* infection was found to trigger mammary tumorigenesis in Apc^{Min/+} in the absence of IBD^{57, 64}. Mammary tumors also developed rapidly in susceptible mice after transfer of CD4⁺ CD45RB^{high} T cells^{57, 63}. While WT Treg completely inhibited *H. hepaticus*-induced diseases in these models, IL-10-deficient Treg cells exacerbated rather than inhibited *H. hepaticus*-induced extra-intestinal pathology^{24, 37}. Interestingly, prior exposures of Treg donor mice to *H. hepaticus* enhanced their ability to inhibit extra-intestinal pathology^{57, 63, 64}, raising the possibility that therapies aimed towards intestinal homeostasis may offer sustained protection from systemic diseases.

Virulence Factors of Enterohepatic Helicobacters

Human IBD as well as IBD in mouse models is multifactorial, with genetic and environmental factors contributing to pathogenesis. The complexity of the system necessitates parallel investigations into bacterial virulence factors, gene expression changes in intestinal tissue, host innate and adaptive immune responses, changes in the gut microbial flora, and of course, lesion development in the intestine. Using the *H. hepaticus* genome, we have begun studying in detail, with the use of isogenic mutants, how different virulence genes play a role in chronic intestinal inflammation. The pathogenic potential of several virulence factors from *H. hepaticus* have been well characterized.

Of the known EHS, *H. hepaticus* strain 3B1 (ATCC 51449), the prototype of EHS, has been the most extensively investigated. This murine pathogen contains a circular genome of ~1.8 Mb with 1875 predicted open reading frames⁶⁵. The G+C content of the *H. hepaticus*

genome is 35.9% which places it between the G+C content of *H. pylori* (39%) and *C. jejuni* (30.5%). In addition, ~ 50% of predicted *H. hepaticus* genes are orthologous to those in the genome of either *H. pylori* or *C. jejuni*, both of which cause significant gastrointestinal diseases in humans⁶⁵.

Cytotoxic distending toxin (CDT)

Bacterial CDTs are present in multiple gram negative pathogens including strains of *Salmonella* spp, *Shigella* spp, *C. jejuni*, and *E. coli*, and belong to the AB₂-type of toxins. In general these toxins are comprised of subunits CdtA and CdtC which together bind subunit CdtB and deliver CdtB, the active subunit of the toxin, intracellularly⁶⁶. Several biological functions of the CdtB subunit have been reported, including a DNase I-like function, cell cycle arrest, phosphatase activity and eventual cell death⁶⁷. The *cdtB* orthologue and CDT activity are found in several enterohepatic helicobacters, including *H. hepaticus*, *H. bilis*, *H. canis*, and *H. marmotae* as well as in *H. cinaedi* and *H. pullorum* isolated from humans⁶⁸⁻⁷⁰.

H. hepaticus 3B1 and an isogenic mutant of the cytolethal distending toxin gene (*cdtB*-deficient HhcdtBm7) were evaluated in outbred Swiss Webster mice. Whereas inoculation with WT 3B1 lead to persistent colonization, colonization by the mutant failed in female mice and was transient in males⁷¹. Wildtype 3B1 infection caused significantly increased expression of ileal and cecal IFN- γ mRNA, higher Th1-induced IgG2a responses, and increased mucosal IgA secretion compared to the isogenic mutant^{13, 71}. CDT-deficient isogenic *H. hepaticus* mutants also lose their ability to persistently colonize the large intestine of B6.129-IL10^{tm1Cgn} (IL10^{-/-}) mice. Importantly, the mutant-infected mice developed significantly less severe typhlocolitis when compared to WT 3B1 infected mice⁷¹⁻⁷³. Mutation of the CDT gene of *H. cinaedi*, a human pathogen, also reduced its ability to induce lower bowel pathology in IL-10-deficient mice⁷⁴.

Molecular mechanisms operable in *H. hepaticus* CDT induced cell death are also being actively investigated. CDT activated the ATM-dependent DNA damage check point response in a myc-dependent fashion⁷⁵. In addition, exposure of INT407 cells to *H. hepaticus* CDT resulted in upregulation or pro-apoptotic Bax, release of Cyt c, and activation of caspases 3/7 and 9⁷⁶. Events operable in *H. hepaticus* CDT-induced cell arrest and apoptosis are summarized in Figure 1.

H. hepaticus pathogenicity island (PAI)

PAIs are distinct genetic elements on bacterial chromosomes that encode one or more virulence-associated factors and often have a G+C content distinct from the rest of the core genome⁶⁵. Several PAIs, such as *LEE* in enteropathogenic *Escherichia coli*, *cag* in *Helicobacter pylori* and *SaPII* in *Staphylococcus aureus*, significantly contribute to pathogenicity of these infectious agents⁷⁷. In the genome of *H. hepaticus* 3B1, a 71-kb region, *HHGII*, displays genetic features characteristic of PAIs⁶⁵. *HHGII* is highly variable among certain *H. hepaticus* isolates. Male A/JCr mice infected with *H. hepaticus* strain MIT 96-1809 lacking the entire *HHGII* or strain MIT 96-284 missing ~62 out of 71-kb of *HHGII* developed less-severe hepatitis than those infected with *H. hepaticus* 3B1 which has an intact *HHGII*⁷⁸. An isogenic mutant (*HhPAId1*) of *H. hepaticus* 3B1 containing a deletion of 19 predicted genes (HH0250 to HH0268) within *HHGII* colonized the intestine of B6.129-IL10^{tm1Cgn} (IL10^{-/-}) mice at higher levels but provoked less severe typhlocolitis and hyperplasia when compared to *H. hepaticus* 3B1⁷⁹. The magnitude of the Th1-associated IgG2c response against this isogenic mutant (*HhPAId1*) was less than against wildtype *H. hepaticus* and was accompanied by suppressed cecal and colonic mRNA expression levels for proinflammatory IFN- γ , TNF- α and IL17a. These results demonstrate

that *HHGII* contributes to the pathogenicity of *H. hepaticus* at least in part via up-regulation of proinflammatory mediators.

Recently, a study indicated that *HHGII* encodes for a set of 12 genes (HH0237, HH0242 to HH0245, HH0247 to HH0252, HH0291) which are homologous to known bacterial type VI secretion systems (T6SS)⁴⁵. T cell-reconstituted *Rag1*^{-/-} mice infected with a T6SS-deficient Δ *IcmF* *H. hepaticus* mutant (encoded by HH0252) developed higher colonization levels of the mutant compared to wildtype *H. hepaticus*-infected mice, consistent with higher levels of mutant *HhPAId1* cecal colonization⁷⁹. In addition, infection with Δ *IcmF* *H. hepaticus* induced higher expression in the colon of proinflammatory mediators including IL-17, IL-23, IL-1 β , TNF α and IFN γ than infection with WT *H. hepaticus* 3B1⁴⁵. However, unlike the *HhPAId1* mutant, the T6SS mutant Δ *IcmF*, and *H. hepaticus* 3B1 induced a similar degree of colitis by 2-4 weeks postinoculation^{45,79}. Therefore, further investigations will be required to define the role(s) of T6SS and additional components in *HHGII* in the pathogenesis of *H. hepaticus*.

Urease

Gastric helicobacters produce urease which is essential for establishing persistent colonization in the acidic milieu of the stomach⁸⁰. Approximately 40% of known EHS species, including *H. hepaticus*, are urease-positive⁸¹. The *H. hepaticus ure* gene cluster is similar to that of *H. pylori*; however, regulatory mechanisms of urease activity in *H. hepaticus* are distinct from those in *H. pylori*. For example, *H. hepaticus* urease does not confer acid-resistance, transcription of *ure* genes is not induced by acid, and urease activity is suppressed by the transcriptional regulator Fur^{82,83}.

By infecting male A/JCr mice with a urease-deficient, isogenic mutant (HhureNT9) of *H. hepaticus* 3B1, we demonstrated that the lack of urease activity did not affect the level of cecal colonization but its presence was essential for hepatic colonization⁸¹. Consequently, the HhureNT9-infected mice developed less severe hepatitis and produced significantly lower hepatic mRNA levels of proinflammatory cytokines IFN- γ and TNF- α when compared to the *H. hepaticus* 3B1-infected mice⁸¹.

Enzymes in oxidative stress resistance

To survive and establish colonization in the host, bacteria have evolved various mechanisms to combat oxidative stress that confers bactericidal effects via reactive oxygen species. The *H. hepaticus* catalase enzyme KatA, which converts hydrogen peroxide into molecular oxygen and water, plays a key role in this process. The amino acid sequence of *H. hepaticus* KatA contains three motifs (R-F-Y-D, RERIPER and VVHAKG) in the haem-ligand domain and three surface-predicted motifs that are shared among bacterial and mammalian catalases⁸⁴. KatA-deficient *H. hepaticus* are more sensitive to exposure of oxygen and H₂O₂ and also suffer severe DNA fragmentation by H₂O₂ treatment compared to *H. hepaticus* 3B1⁸⁵.

Bacterial hydrogenase, a hydrogen uptake hydrogenase, oxidizes molecular hydrogen to yield protons and electrons which have a key role in energy conservation in bacteria. *H. hepaticus* genes or HH0056 to HH0059 encode subunits of hydrogenase HyaA to HyaD. Mutation in the *H. hepaticus hyaB* (coding for the large subunit) does not affect cecal and hepatic colonization levels when compared to *H. hepaticus* 3B1 in male A/JCr mice; however, liver pathology is diminished in the *hyaB* mutant-infected mice⁸⁶. It is unknown how hydrogenase contributes to the pathogenesis of *H. hepaticus*, but it is speculated that energy released by hydrogen oxidation may be utilized to promote synthesis of virulence-related proteins or enzymes that result in hepatic or intestinal inflammation and necrosis⁸⁶.

Flagellar genes

All *Helicobacter* species possess flagella for motility; *H. hepaticus* is a spiral rod with bipolar sheathed flagella. In other related bacteria, flagellar genes are mainly regulated by the sigma factor FliA (σ_{28}). *H. hepaticus* contains two identical copies of the gene encoding the major flagellin subunit FlaA (open reading frames HH1364 [flaA1] and HH1653 [flaA2])⁶⁵, which is regulated by the sigma factor FliA (σ_{28}). Mutations in *fliA* or both copies of the *flaA* gene resulted in no detectable synthesis of FlaA as well as severely truncated flagella, thus both mutants were nonmotile and unable to colonize mice⁸⁷. The *flaA_1 H. hepaticus* mutant, which has flagella but decreased motility, also does not colonize mice, indicating that full motility is a prerequisite for intestinal colonization by *H. hepaticus*, and that the presence of flagella alone is not sufficient.

Summary

As described in this review, *Helicobacter hepaticus* has played a central role in shaping our understanding of how intestinal microbiota interact with the host to produce both inflammatory and tolerant responses. The study of immunopathology that develops following *H. hepaticus* infection of susceptible mice has helped to define the importance of key inflammatory mediators including IL-23 and IL-17, and highlighted the importance of the innate immune response in the development of chronic intestinal inflammation. The use of *H. hepaticus* infection models has provided definitive evidence that regulatory T cells directly inhibit the innate inflammatory response to lower bowel microbiota and delineated the critical role of IL-10 in this process. Remarkably, *H. hepaticus* infection has powerful effects on carcinogenesis both within the intestine and at extraintestinal sites, and many of the same immunoregulatory pathways that influence the gastrointestinal inflammatory response to *H. hepaticus* also appear to influence the development of cancer. The complete genomic sequence of *H. hepaticus* has advanced the identification of potential virulence factors, and evaluating the function of these factors is ongoing. In addition, genome sequencing of five additional EHS isolated from humans with gastrointestinal disease (*H. bilis*, *H. canadensis*, *H. cinaedi*, *H. pullorum* and *H. winghamensis*) has been completed and these results can be found at http://www.broadinstitute.org/annotation/genome/Helicobacter_group/. Comparative genome analysis of these 5 genomes plus *H. hepaticus* will provide insight into the etiopathogenesis of EHS infection in humans. For example, preliminary data indicates that both *H. cinaedi* and *H. pullorum* have the existence of PAI's with similar features to the HHGI found in *H. hepaticus*. Studies are needed to ascertain whether these PAI's impart similar in vivo characteristics in humans. Additional areas for future investigation include defining the cellular and molecular pathways that contribute to host recognition of *H. hepaticus*, and determining how initial recognition events lead to activation of innate and acquired inflammatory effector mechanisms. Further, clarifying how responses to *H. hepaticus* infection influences carcinogenesis at local and distant sites could lead to important new insights into the relationship between specific microbiota and the development of cancer. Finally, delineating the targets of *H. hepaticus* associated virulence factors could lead to novel approaches to treating microbial induced inflammation in the lower bowel.

Acknowledgments

Grant Support

R01-DK052413 (JGF), P01-CA026731 (JGF), R01-CA067529 (JGF), P30-ES02109 (JGF), R01-A1052267 (BH, SE), R01-CA108854 (SE)

References

1. Fox JG, et al. *Helicobacter hepaticus* sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. *J Clin Microbiol.* 1994; 1238:1238–1245. [PubMed: 8051250]
2. Ward JM, et al. Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel *Helicobacter* species. *J Natl Cancer Inst.* 1994; 1222:1222–1227. [PubMed: 8040890]
3. Fox JG, et al. Chronic proliferative hepatitis in A/JCr mice associated with persistent *Helicobacter hepaticus* infection: a model of *helicobacter*-induced carcinogenesis. *Infect Immun.* 1996; 1548:1548–1558. [PubMed: 8613359]
4. Boutin SR, et al. *Helicobacter pullorum* outbreak in C57BL/6NTac and C3H/HeNTac barrier-maintained mice. *J Clin Microbiol.* 48:1908–1910. [PubMed: 20220161]
5. Shames B, et al. Identification of widespread *Helicobacter hepaticus* infection in feces in commercial mouse colonies by culture and PCR assay. *J Clin Microbiol.* 1995; 2968:2968–2972. [PubMed: 8576355]
6. Taylor NS, Xu S, Nambiar P, Dewhirst FE, Fox JG. Enterohepatic *Helicobacter* species are prevalent in mice from commercial and academic institutions in Asia, Europe, and North America. *J Clin Microbiol.* 2007; 2166:2166–2172. [PubMed: 17507523]
7. Berg DJ, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. *J Clin Invest.* 1996; 1010:1010–1020. [PubMed: 8770874]
8. Ward JM, et al. Inflammatory large bowel disease in immunodeficient mice naturally infected with *Helicobacter hepaticus*. *Lab Anim Sci.* 1996; 15:15–20. [PubMed: 8699813]
9. Foltz CJ, et al. Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by *Helicobacter hepaticus*. *Helicobacter.* 1998; 69:69–78. [PubMed: 9631303]
10. Cahill RJ, et al. Inflammatory bowel disease: an immunity-mediated condition triggered by bacterial infection with *Helicobacter hepaticus*. *Infect Immun.* 1997; 3126:3126–3131. [PubMed: 9234764]
11. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 *scid* mice. *Int Immunol.* 1993; 1461:1461–1471. [PubMed: 7903159]
12. Powrie F, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in *scid* mice reconstituted with CD45RBhi CD4+ T cells. *Immunity.* 1994; 553:553–562. [PubMed: 7600284]
13. Kullberg MC, et al. *Helicobacter hepaticus* triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. *Infect Immun.* 1998; 5157:5157–5166. [PubMed: 9784517]
14. Burich A, et al. *Helicobacter*-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. *Am J Physiol Gastrointest Liver Physiol.* 2001; 281:G764–778. [PubMed: 11518689]
15. Erdman SE, Horwitz B, Poutahidis T, Rogers AB, Fox JG. *Helicobacter* induced adenocarcinoma in the colon of NFkB deficient mice. *Gastroenterology.* 2002; 122:A429.
16. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell.* 1993; 263:263–274. [PubMed: 8402911]
17. Dieleman LA, et al. *Helicobacter hepaticus* does not induce or potentiate colitis in interleukin-10-deficient mice. *Infect Immun.* 2000; 5107:5107–5113. [PubMed: 10948132]
18. Kullberg MC, et al. *Helicobacter hepaticus*-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. *Infect Immun.* 2001; 4232:4232–4241. [PubMed: 11401959]
19. Kullberg MC, et al. IL-23 plays a key role in *Helicobacter hepaticus*-induced T cell-dependent colitis. *J Exp Med.* 2006; 2485:2485–2494. [PubMed: 17030948]
20. Leppkes M, et al. ROR gamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. *Gastroenterology.* 2009; 257:257–267. [PubMed: 18992745]

21. O'Connor W Jr, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. *Nat Immunol.* 2009; 603:603–609. [PubMed: 19448631]
22. Zenewicz LA, et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. *Immunity.* 2008; 947:947–957. [PubMed: 19100701]
23. Sugimoto K, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. *J Clin Invest.* 2008; 534:534–544. [PubMed: 18172556]
24. Erdman SE, et al. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. *Cancer Res.* 2003; 6042:6042–6050. [PubMed: 14522933]
25. Maloy KJ, et al. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. *J Exp Med.* 2003; 111:111–119. [PubMed: 12515818]
26. Tomczak MF, et al. NF-kappa B is required within the innate immune system to inhibit microflora-induced colitis and expression of IL-12 p40. *J Immunol.* 2003; 1484:1484–1492. [PubMed: 12874241]
27. von Freeden-Jeffry U, et al. IL-7 deficiency prevents development of a non-T cell non-B cell-mediated colitis. *J Immunol.* 1998; 5673:5673–5680. [PubMed: 9820548]
28. Erdman SE, et al. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. *Am J Pathol.* 2003; 691:691–702. [PubMed: 12547727]
29. Hue S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. *J Exp Med.* 2006; 2473:2473–2483. [PubMed: 17030949]
30. Buonocore S, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. *Nature.* 2010; 1371:1371–1375. [PubMed: 20393462]
31. Eberl G, Littman DR. Thymic origin of intestinal alphabeta T cells revealed by fate mapping of RORgammat+ cells. *Science.* 2004; 248:248–251. [PubMed: 15247480]
32. Eberl G, et al. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. *Nat Immunol.* 2004; 64:64–73. [PubMed: 14691482]
33. Ivanov II, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell.* 2006; 1121:1121–1133. [PubMed: 16990136]
34. Adachi S, et al. Essential role of IL-7 receptor alpha in the formation of Peyer's patch anlage. *Int Immunol.* 1998; 1:1–6. [PubMed: 9488150]
35. Maloy KJ, Antonelli LR, Lefevre M, Powrie F. Cure of innate intestinal immune pathology by CD4+CD25+ regulatory T cells. *Immunol Lett.* 2005; 189:189–192. [PubMed: 15752557]
36. Kullberg MC, et al. Bacteria-triggered CD4(+) T regulatory cells suppress *Helicobacter hepaticus*-induced colitis. *J Exp Med.* 2002; 505:505–515. [PubMed: 12186842]
37. Poutahidis T, et al. Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. *Carcinogenesis.* 2007; 2614:2614–2623. [PubMed: 17724375]
38. Tomczak MF, et al. Defective activation of ERK in macrophages lacking the p50/p105 subunit of NF-kappaB is responsible for elevated expression of IL-12 p40 observed after challenge with *Helicobacter hepaticus*. *J Immunol.* 2006; 1244:1244–1251. [PubMed: 16394015]
39. Wang Y, et al. c-Rel is essential for the development of innate and T cell-induced colitis. *J Immunol.* 2008; 8118:8118–8125. [PubMed: 18523276]
40. Tomczak MF, et al. Inhibition of *Helicobacter hepaticus*-induced colitis by IL-10 requires the p50/p105 subunit of NF-kappa B. *J Immunol.* 2006; 7332:7332–7339. [PubMed: 17082652]
41. Mandell L, et al. Intact gram-negative *Helicobacter pylori*, *Helicobacter felis*, and *Helicobacter hepaticus* bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. *Infect Immun.* 2004; 6446:6446–6454. [PubMed: 15501775]
42. Boulard O, Asquith MJ, Powrie F, Maloy KJ. TLR2-independent induction and regulation of chronic intestinal inflammation. *Eur J Immunol.* 2009; 516:516–524.
43. Asquith MJ, Boulard O, Powrie F, Maloy KJ. Pathogenic and Protective Roles of MyD88 in Leukocytes and Epithelial Cells in Mouse Models of Inflammatory Bowel Disease. *Gastroenterology.* 2010; 519:519–529. [PubMed: 20433840]
44. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. *Nat Immunol.* 2006; 1250:1250–1257. [PubMed: 17110941]

45. Chow J, Mazmanian SK. A pathobiont of the microbiota balances host colonization and intestinal inflammation. *Cell Host Microbe*. 2010; 265:265–276. [PubMed: 20413095]
46. Chaouche-Drider N, et al. A commensal *Helicobacter* sp. of the rodent intestinal flora activates TLR2 and NOD1 responses in epithelial cells. *PLoS One*. 2009; 4:e5396. [PubMed: 19401779]
47. Sterzenbach T, et al. Inhibitory effect of enterohepatic *Helicobacter hepaticus* on innate immune responses of mouse intestinal epithelial cells. *Infect Immun*. 2007; 2717:2717–2728. [PubMed: 17371851]
48. Petnicki-Ocwieja T, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. *Proc Natl Acad Sci U S A*. 2009; 15813:15813–15818. [PubMed: 19805227]
49. Garcia A, et al. Genetic susceptibility to chronic hepatitis is inherited codominantly in *Helicobacter hepaticus*-infected AB6F1 and B6AF1 hybrid male mice, and progression to hepatocellular carcinoma is linked to hepatic expression of lipogenic genes and immune function-associated networks. *Infect Immun*. 2008; 1866:1866–1876. [PubMed: 18285497]
50. Ihrig M, Schrenzel MD, Fox JG. Differential susceptibility to hepatic inflammation and proliferation in AXB recombinant inbred mice chronically infected with *Helicobacter hepaticus*. *Am J Pathol*. 1999; 571:571–582. [PubMed: 10433949]
51. Ward JM, Anver MR, Haines DC, Benveniste RE. Chronic active hepatitis in mice caused by *Helicobacter hepaticus*. *Am J Pathol*. 1994; 959:959–968. [PubMed: 7943185]
52. Fox JG, et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. *Gut*. 2010; 88:88–97. [PubMed: 19850960]
53. Engle SJ, et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. *Cancer Res*. 2002; 6362:6362–6366. [PubMed: 12438215]
54. Boivin GP, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. *Gastroenterology*. 2003; 762:762–777. [PubMed: 12612914]
55. Riddell RH, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Hum Pathol*. 1983; 931:931–968. [PubMed: 6629368]
56. Erdman SE, et al. Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in *Helicobacter hepaticus*-infected, Rag2-deficient mice. *Proc Natl Acad Sci U S A*. 2009; 1027:1027–1032. [PubMed: 19164562]
57. Rao VP, et al. Innate immune inflammatory response against enteric bacteria *Helicobacter hepaticus* induces mammary adenocarcinoma in mice. *Cancer Res*. 2006; 7395:7395–7400. [PubMed: 16885333]
58. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. *Science*. 1990; 322:322–324. [PubMed: 2296722]
59. Erdman SE, et al. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. *Cancer Res*. 2005; 3998:3998–4004. [PubMed: 15899788]
60. Rao VP, et al. Proinflammatory CD4+ CD45RB(hi) lymphocytes promote mammary and intestinal carcinogenesis in Apc(Min/+) mice. *Cancer Res*. 2006; 57:57–61. [PubMed: 16397216]
61. Newman JV, Kosaka T, Sheppard BJ, Fox JG, Schauer DB. Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice. *J Infect Dis*. 2001; 227:227–230. [PubMed: 11424022]
62. Wu S, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nat Med*. 2009; 1016:1016–1022. [PubMed: 19701202]
63. Erdman SE, et al. Unifying roles for regulatory T cells and inflammation in cancer. *Int J Cancer*. 2010; 1651:1651–1665. [PubMed: 19795459]
64. Rao VP, Poutahidis T, Fox JG, Erdman SE. Breast cancer: should gastrointestinal bacteria be on our radar screen? *Cancer Res*. 2007; 847:847–850. [PubMed: 17283110]
65. Suerbaum S, et al. The complete genome sequence of the carcinogenic bacterium *Helicobacter hepaticus*. *Proc Natl Acad Sci U S A*. 2003; 7901:7901–7906. [PubMed: 12810954]
66. Smith JL, Bayles DO. The contribution of cytolethal distending toxin to bacterial pathogenesis. *Crit Rev Microbiol*. 2006; 227:227–248. [PubMed: 17123907]
67. Ge Z, Schauer DB, Fox JG. In vivo virulence properties of bacterial cytolethal-distending toxin. *Cell Microbiol*. 2008; 1599:1599–1607. [PubMed: 18489725]

68. Chien CC, et al. Identification of *cdtB* homologues and cytolethal distending toxin activity in enterohepatic *Helicobacter* spp. *J Med Microbiol.* 2000; 525:525–534. [PubMed: 10847206]
69. Taylor NS, Ge Z, Shen Z, Dewhirst FE, Fox JG. Cytolethal distending toxin: a potential virulence factor for *Helicobacter cinaedi*. *J Infect Dis.* 2003; 1892:1892–1897. [PubMed: 14673770]
70. Young VB, et al. Cytolethal distending toxin in avian and human isolates of *Helicobacter pullorum*. *J Infect Dis.* 2000; 620:620–623. [PubMed: 10915100]
71. Ge Z, et al. Cytolethal distending toxin is essential for *Helicobacter hepaticus* colonization in outbred Swiss Webster mice. *Infect Immun.* 2005; 3559:3559–3567. [PubMed: 15908385]
72. Pratt JS, Sachen KL, Wood HD, Eaton KA, Young VB. Modulation of host immune responses by the cytolethal distending toxin of *Helicobacter hepaticus*. *Infect Immun.* 2006; 4496:4496–4504. [PubMed: 16861635]
73. Young VB, et al. In vitro and in vivo characterization of *Helicobacter hepaticus* cytolethal distending toxin mutants. *Infect Immun.* 2004; 2521:2521–2527. [PubMed: 15102759]
74. Shen Z, et al. Cytolethal distending toxin promotes *Helicobacter cinaedi*-associated typhlocolitis in interleukin-10-deficient mice. *Infect Immun.* 2009; 2508:2508–2516. [PubMed: 19307212]
75. Guerra L, et al. Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage. *PLoS One.* 2010; 5:e8924. [PubMed: 20111719]
76. Liyanage NP, et al. *Helicobacter hepaticus* cytolethal distending toxin causes cell death in intestinal epithelial cells via mitochondrial apoptotic pathway. *Helicobacter.* 2010; 98:98–107. [PubMed: 20402812]
77. Gal-Mor O, Finlay BB. Pathogenicity islands: a molecular toolbox for bacterial virulence. *Cell Microbiol.* 2006; 1707:1707–1719. [PubMed: 16939533]
78. Boutin SR, et al. Different *Helicobacter hepaticus* strains with variable genomic content induce various degrees of hepatitis. *Infect Immun.* 2005; 8449:8449–8452. [PubMed: 16299349]
79. Ge Z, et al. *Helicobacter hepaticus* HHG11 is a pathogenicity island associated with typhlocolitis in B6.129-IL10 tm1Cgn mice. *Microbes Infect.* 2008; 726:726–733. [PubMed: 18538610]
80. Burne RA, Chen YY. Bacterial ureases in infectious diseases. *Microbes Infect.* 2000; 533:533–542. [PubMed: 10865198]
81. Ge Z, et al. *Helicobacter hepaticus* urease is not required for intestinal colonization but promotes hepatic inflammation in male A/JCr mice. *Microb Pathog.* 2008; 18:18–24. [PubMed: 18486436]
82. Belzer C, et al. Differential regulation of urease activity in *Helicobacter hepaticus* and *Helicobacter pylori*. *Microbiology.* 2005; 3989:3989–3995. [PubMed: 16339943]
83. Belzer C, van Schendel BA, Kuipers EJ, Kusters JG, van Vliet AH. Iron-responsive repression of urease expression in *Helicobacter hepaticus* is mediated by the transcriptional regulator Fur. *Infect Immun.* 2007; 745:745–752. [PubMed: 17101656]
84. Alyamani EJ, et al. *Helicobacter hepaticus* catalase shares surface-predicted epitopes with mammalian catalases. *Microbiology.* 2007; 1006:1006–1016. [PubMed: 17379710]
85. Hong Y, Wang G, Maier RJ. A *Helicobacter hepaticus* catalase mutant is hypersensitive to oxidative stress and suffers increased DNA damage. *J Med Microbiol.* 2007; 557:557–562. [PubMed: 17374900]
86. Mehta NS, Benoit S, Mysore JV, Sousa RS, Maier RJ. *Helicobacter hepaticus* hydrogenase mutants are deficient in hydrogen-supported amino acid uptake and in causing liver lesions in A/J mice. *Infect Immun.* 2005; 5311:5311–5318. [PubMed: 16113246]
87. Sterzenbach T, et al. Role of the *Helicobacter hepaticus* flagellar sigma factor FliA in gene regulation and murine colonization. *J Bacteriol.* 2008; 6398:6398–6408. [PubMed: 18689480]
88. Chin EY, Dangler CA, Fox JG, Schauer DB. *Helicobacter hepaticus* infection triggers inflammatory bowel disease in T cell receptor alpha|beta mutant mice. *Comp Med.* 2000; 586:586–594. [PubMed: 11200563]
89. Shomer NH, Dangler CA, Schrenzel MD, Fox JG. *Helicobacter bilis*-induced inflammatory bowel disease in *scid* mice with defined flora. *Infect Immun.* 1997; 4858:4858–4864. [PubMed: 9353076]

90. Shomer NH, Dangler CA, Marini RP, Fox JG. *Helicobacter bilis*/*Helicobacter rodentium* co-infection associated with diarrhea in a colony of *scid* mice. *Lab Anim Sci*. 1998; 455:455–459. [PubMed: 10090057]
91. Fox JG, et al. Persistent hepatitis and enterocolitis in germfree mice infected with *Helicobacter hepaticus*. *Infect Immun*. 1996; 3673:3673–3681. [PubMed: 8751916]
92. Erdman S, Fox JG, Dangler CA, Feldman D, Horwitz BH. Typhlocolitis in NF-kappa B-deficient mice. *J Immunol*. 2001; 1443:1443–1447. [PubMed: 11160181]
93. Maggio-Price L, et al. *Helicobacter bilis* infection accelerates and *H. hsource>paticus* infection delays the development of colitis in multiple drug resistance-deficient (*mdr1a*^{-/-}) mice. *Am J Pathol*. 2002; 739:739–751. [PubMed: 11839595]
94. Maggio-Price L, et al. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. *Cancer Res*. 2006; 828:828–838. [PubMed: 16424015]
95. Fox JG, et al. A novel urease-negative *Helicobacter* species associated with colitis and typhlitis in IL-10-deficient mice. *Infect Immun*. 1999; 1757:1757–1762. [PubMed: 10085015]
96. Franklin CL, et al. *Helicobacter typhlonius* sp. nov., a Novel Murine Urease-Negative Helicobacter Species. *J Clin Microbiol*. 2001; 3920:3920–3926. [PubMed: 11682508]
97. Whary MT, et al. Rapid onset of ulcerative typhlocolitis in B6.129P2-IL10tm1Cgn (IL-10^{-/-}) mice infected with *Helicobacter trogontum* is associated with decreased colonization by altered Schaedler's flora. *Infect Immun*. 2006; 6615:6615–6623. [PubMed: 16982822]




Figure 1.

ATM-dependent checkpoint responses and apoptosis triggered by *H. hepaticus* CDT-induced DNA damage^{75, 76}. DSB, double strand breakage; Nbs 1, Nijmegen Breakage Syndrome 1 protein; ATM, Ataxia Telangiectasia Mutated; CHK2, checkpoint kinase 2; Bcl2, B-cell leukemia/lymphoma 2; Bax, Bcl-2-associated X protein; Cyt *c*, Cytochrome *c*; Apaf-1, apoptotic peptidase activating factor 1.

Table 1

H. hepaticus- and *H. bilis*-associated IBD in mice^a

Genetic status of mice	Type of defect	Pathology	Reference
CD45RB (high)-reconstituted ICR defined flora <i>scids</i>	Reconstitution with naïve CD4 ⁺ T cell	Typhlocolitis	10
TCR α , B mutants	Abnormal T cell receptors	Typhlocolitis	88
Scid ICR-defined flora ^b	Lack T and B cell	Typhlocolitis	89, 90
C57BL/IL-10 ^{-/-c}	Knockout	Typhlocolitis	14, 18, 19, 36
129SvEv/Rag2 ^{-/-}	Knockout	Typhlocolitis, colon cancer	28, 56
C57BLRag2 ^{-/-}	Knockout	Typhlocolitis	14
IL-7 ^{-/-} /RAG-2 ^{-/-}	Double Knockout	None	27
A/JCr	Normal	Typhlitis	3
Swiss Webster gnotobiotic	Normal	Enterocolitis	91
129SvEv/NF- κ B (p50 ^{-/-} p65 ^{+/-})	Double Knockout	Typhlocolitis	92
<i>mdrla</i> ^{-/-d}	Lack P-glycoprotein	Typhlocolitis	93
SMAD3 ^{-/-d}	Knockout	Typhlocolitis, colon cancer	94

^aIn mice of the same genetic status which had *H. hepaticus* (or other *Helicobacter* spp.)-negative microflora, no intestinal disease was noted.

^bMice infected with *H. bilis* also produced IBD⁸⁹.

^cIBD also produced in C57BL/IL-10^{-/-} mice experimentally infected with a novel urease-negative *Helicobacter* sp.⁹⁵; now named *H. typhlonius*⁹⁶; also IBD produced with *H. trogonum*⁹⁷ and *H. cinaedi*⁷⁴.

^d*H. bilis* produces IBD^{93, 94}, and colon cancer⁹⁴.